Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?

Shen, Helen M.; D’Souza, Amber M.; Green, Ian F.; Pohar, Kamal S.; Mortazavi, Amir; Zynger, Debra L.

doi:10.1016/j.humpath.2015.05.020

Cited by 4 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others studies, for example, included patients who received neoadjuvant chemotherapy . On one hand, this may have led to an increased selection of variant UCB histology at RC due to improved eradication of pure UCB with cisplatin‐based chemotherapy . On the other hand, it may also have prolonged survival in some patients with variant histologies (e.g.…”

Section: Discussionmentioning

confidence: 99%

Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Interestingly, it has been described that a higher amount of variant histology in RC specimens is seen after NAC than in transurethral resection of bladder tumor (TURBT) specimens; however, the percentage of variant histology on TURBT specimen was not associated with NAC pathological response. Similarly, mitotic proliferation was found to be lower after NAC, but pre-NAC mitotic rate was not a predictor of response [23]. A comprehensive analysis of different variants was performed with the data of 369 patients with different histological variants who received NAC.…”

Section: Pathological Classificationmentioning

confidence: 99%

Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer

Motterle

Andrews

Morlacco

et al. 2020

European Urology Focus

View full text Add to dashboard Cite

“…Pathologic complete response was reported in ten studies (4-6,8,10-14,36) while pathologic downstaging was reported in nine studies (4,5,7,8,10,11,(13)(14)(15). S u r v i v a l b e n e f i t w i t h N A C i n V H o f U C w a s demonstrated in two studies (5,14), and specifically with sarcomatoid differentiation (11) and squamous differentiation (6,9).…”

Section: Actual Resultsmentioning

confidence: 99%

“…Nineteen studies (5,6,(8)(9)(10)13,16,17,19,21,23,24,27,(29)(30)(31)33,41,42) analyzed independent factors other than VH affecting either response to treatment or survival outcomes. Age, lymphovascular invasion, hydronephrosis, nodal metastasis and pathological/clinical stage were the most commonly reported factors.…”

Section: Actual Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes

Ogbue

Haddad²,

Almassi³

et al. 2022

Transl Androl Urol

View full text Add to dashboard Cite

Background and Objective: The histologic variants of urothelial carcinoma (UC) are tumors arising from within the urothelium in which some component of the tumor morphology is other than urothelial.They are underdiagnosed, aggressive and have varying pathologic response rates to systemic chemotherapy.There are no consensus guidelines on the use of systemic chemotherapy in variant histology (VH) of UC. We performed a contemporary review on pathologic response rates to neoadjuvant systemic therapy and survival outcomes following radical cystectomy in order to provide a rationale for clinical practice recommendations on the management of UC with VH.Methods: A PubMed literature search was conducted for all English articles from inception reporting either pathological response rates to neoadjuvant treatment or survival outcomes after radical cystectomy in non-metastatic VH of UC.Key Content and Findings: Neoadjuvant chemotherapy (NAC) prior to radical cystectomy was shown to be a beneficial treatment strategy in UC with VH. The micropapillary, plasmacytoid, nested and sarcomatoid histologic variants were associated with worse survival outcomes compared to conventional UC and UC with squamous or glandular differentiation despite initial downstaging with chemotherapy. There is evidence of improved survival in patients with sarcomatoid differentiation receiving NAC compared to RC alone. The major prognostic factors that affect survival outcomes in VH of UC include histologic variant subtype, patient age, presence of lymphovascular invasion, hydronephrosis, nodal metastasis and advanced T stage at diagnosis. Recent studies demonstrate that VH of UC are heterogenous tumors and responsiveness to NAC may be a function of the molecular subtypes present.Conclusions: Based on these findings, NAC to achieve pathologic downstaging prior to radical cystectomy is recommended for MIBC with VH. Biomarkers identified by molecular profiling with immunohistochemistry will need to be validated as predictors of response to NAC in future trials.

show abstract

Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?

Cited by 4 publications

References 25 publications

Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy

Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy

Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer

Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes

Contact Info

Product

Resources

About